The active substance is acetylsalicylic acid.
1 tablet contains 75 mg of acetylsalicylic acid. Excipients: microcrystalline cellulose, colloidal silica anhydrous, pregelatinised corn starch, talc, hypromelose, titanium dioxide (E 6 171), triacetin, copolymer of methacrylic acid and ethyl acrylate, triethyl citrate, colloidal silica anhydrous, sodium bicarbonate, sodium lauryl sulphate.
Ischaemic heart disease (Coronary Heart Disease) and all clinical situations requiring inhibition of platelet aggregation:
– prevention of myocardial infarction in high-risk patients,
– recent or suspected recent myocardial infarction,
– history of unstable coronary heart disease,
– secondary prevention following myocardial infarction,
– conditions following coronary artery bypass grafting, coronary angioplasty,
– prevention of transient ischaemic attacks (TIA) and ischaemic stroke in TIA patients,
– after ischaemic stroke in patients with TIA,
– in patients with peripheral artery obstructive disease,
– prevention of venous thrombosis and pulmonary embolism in immobilised patients, e.g. following major surgical procedures in addition to other prevention methods.
Hypersensitivity to the active substance or any of the excipients.
This is a drug. For safety, use it according to the package insert and only when necessary. If in doubt, consult your doctor or pharmacist.
This is a drug. For safety, use it according to the package insert and only when necessary. If in doubt, consult your doctor or pharmacist.
phone: (+48 22) 742 00 22
informacjaoleku@hasco-lek.pl
The active substance is acetylsalicylic acid.
1 tablet contains 75 mg of acetylsalicylic acid. Excipients: microcrystalline cellulose, colloidal silica anhydrous, pregelatinised corn starch, talc, hypromelose, titanium dioxide (E 6 171), triacetin, copolymer of methacrylic acid and ethyl acrylate, triethyl citrate, colloidal silica anhydrous, sodium bicarbonate, sodium lauryl sulphate.
Ischaemic heart disease (Coronary Heart Disease) and all clinical situations requiring inhibition of platelet aggregation:
– prevention of myocardial infarction in high-risk patients,
– recent or suspected recent myocardial infarction,
– history of unstable coronary heart disease,
– secondary prevention following myocardial infarction,
– conditions following coronary artery bypass grafting, coronary angioplasty,
– prevention of transient ischaemic attacks (TIA) and ischaemic stroke in TIA patients,
– after ischaemic stroke in patients with TIA,
– in patients with peripheral artery obstructive disease,
– prevention of venous thrombosis and pulmonary embolism in immobilised patients, e.g. following major surgical procedures in addition to other prevention methods.
Hypersensitivity to the active substance or any of the excipients.
Przedsiębiorstwo Produkcji
Farmaceutycznej
Hasco-Lek S.A.
st. Żmigrodzka 242e
51-131 Wroclaw
phone: (+48) 71 352 95 22
fax: (+48) 71 352 76 36
hasco@hasco-lek.pl
